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SIONS: With the exception of ﬂuoxetine, our sample of
NF residents showed that weight gains with mirtazapine
were not statistically different from other non-TCA 
antidepressants once factors such as baseline weight,
gender, dose and co-morbid diagnoses are controlled for 
statistically.
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EVALUATING THE EFFECTIVENESS OF
FLUOXETINE 90MG ADMINISTERED EVERY
WEEK AND EVERY 2 WEEKS IN NURSING HOME
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OBJECTIVE: To evaluate the effectiveness of ﬂuoxetine
90mg every week/every 2 weeks in elderly nursing home
residents. METHOD: Twenty patients were randomly
selected who had been stabilized on 20mg ﬂuoxetine
daily for 3 months were switched to ﬂuoxetine 90mg
every week. An additional 20 patients were randomly
selected who had been stabilized on 10mg ﬂuoxetine
daily for 3 months and switched to ﬂuoxetine 90mg every
2 weeks. The Geriutric Depression Scale (GDS) was
administered to all patients to assess effectiveness one
week before and six weeks after the switch. Costs were
calculated as drug acquisition cost, nursing time, and
pharmacy time. Generic ﬂuoxetine was used in both cases
for 3 months prior to switching to ﬂuoxetine 90mg
weekly. RESULTS: Subject Characteristics: Fluoxetine
Weekly Group/Fluoxetine Every 2 Week Group Respec-
tively: Age: 81 + 8/82 + 9, Sex: 14 females/8 females, Eth-
nicity: 6% AA, 1% Hispanic/7% AA, 1% Hispanic.
Effectiveness: There was no statistically signiﬁcant differ-
ence in GDS scores before or after the switch for either
the ﬂuoxetine 90mg weekly group or the ﬂuoxetine 90
mg every 2 weeks group. Costs: Costs ($) for a 2-week
period before and after the switch were as follows: Flu-
oxetine 90mg Weekly Before/After Respectively: Drug
acquisition costs—1.68/33.38, Nursing costs—21.00/
3.00, Pharmacy costs—23.38/3.34, Total—46.06/39.72,
P > 0.05. Fluoxetine 90mg every 2 weeks Before/After
Respectively: Drug acquisition costs—0.84/16.69,
Nursing costs—21.00/1.50, Pharmacy costs—23.38/
3.34, Total—45.22/19.03, P < .05. CONCLUSION: This
suggests that ﬂuoxetine 90mg weekly and ﬂuoxetine 90
mg every 2 weeks are effective in nursing home patients.
The costs associated with the administration of medica-
tion may be a more signiﬁcant factor to consider when
evaluating cost effectiveness. Our ﬁndings are limited by
the small sample size and did not account for other costs
due to adverse effects, noncompliance, and medication
errors.
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OBJECTIVES: Atypical antipsychotic (AAP) drugs are
recommended as a ﬁrst-line pharmacotherapeutic strat-
egy for schizophrenia. Although these drugs offer an
improved neurological side-effect proﬁle, they can be
associated with important weight gain, increased serum
triglyceride levels, glucose intolerance, and diabetes 
mellitus. Clustering of these effects is associated with the
metabolic syndrome, which can greatly increase the risk
of coronary heart disease (CHD). The objective of this
study was to examine the impact of metabolic induced
changes by AAPs on the development of CHD in schizo-
phrenic patients. METHODS: A Markov model was 
constructed using disease state probabilities derived 
from published PROCAM logistic regression model and
published literature to link risk factors to disease inci-
dence in order to estimate the risk of developing CHD.
Based on the presence or absence of potential CHD risk
factors, persons were assigned transition probabilities 
of remaining in good health or moving into develop-
ing CHD (absorbing phase). The main outcome of the 
study was the risk of developing CHD in a hypothetical
cohort, and in turn, to estimate the proportion remaining
disease-free. RESULTS: The relative risk of CHD associ-
ated with triglyceride level and obesity was examined.
Clustering of these two metabolic effects, seen in patients
treated with certain AAPs, is associated with a two-fold
increased risk of CHD in men. The model generated real-
istic results, which are in total agreement with previously
published literature. CONCLUSIONS: This model can be
used as an effective instrument for assisting in the care of
persons at high risk of CHD. Moreover, it can be used to
estimate the impact of AAP induced metabolic changes
on the risk of CHD in individual patients. Physicians can
also use this tool to assess the beneﬁt/risk ratio of patients
that respond well to AAPs but develop metabolic side
effects.
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Objective: To assess recent pharmacologic treatment pat-
terns for hospitalized bipolar patients. METHODS: Using
